Development of Quality of Life Questionnaire for Patients with Parkinson’s Disease Undergoing STN-DBS

In device-aided therapy (DAT) for Parkinson’s disease (PD), factors such as device-related adverse effects, psychological and lifestyle changes, and specific disease progression can affect the quality of life (QoL) of patients with advanced PD. However, there is no existing QoL scale that includes the effects of therapeutic devices. From a semi-structured interview with patients with PD undergoing deep brain stimulation (DBS), we extracted the content of utterances that were thought to affect the QoL and created a draft questionnaire consisting of 113 items. This questionnaire was administered to 54 other patients undergoing DBS, whose data were examined for reliability and validity by factor analysis, and finally, a 24-item PD QoL questionnaire for patients on DAT (PDQ-DAT) was developed. Presently, the PDQ-DAT is the only scale that can assess the QoL of patients on DAT, including the influence treatment devices have on them. In the future, it might be used to help in shared decision-making in medicine by incorporating the patient’s sense of burden and values in the selection of treatment methods.

[1]  Yi Bao,et al.  Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis , 2019, Front. Neurol..

[2]  M. Rizzone,et al.  Long‐term effect of levodopa‐carbidopa intestinal gel on axial signs in Parkinson’s disease , 2019, Acta neurologica Scandinavica.

[3]  S. Marino,et al.  Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers , 2018, Journal of Neurology.

[4]  H. Reichmann,et al.  Medical and surgical management of advanced Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[5]  M. Merello,et al.  Challenges in PD Patient Management After DBS: A Pragmatic Review , 2018, Movement disorders clinical practice.

[6]  E. Pekkonen,et al.  Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease , 2017, Brain and behavior.

[7]  F. Marrosu,et al.  Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease. , 2017, Parkinsonism & related disorders.

[8]  G. Deuschl,et al.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review , 2013, Journal of Neurology.

[9]  P. Pollak,et al.  Effects of varying subthalamic nucleus stimulation on apraxia of lid opening in Parkinson’s disease , 2012, Journal of Neurology.

[10]  E. Racine,et al.  A Review of Social and Relational Aspects of Deep Brain Stimulation in Parkinson's Disease Informed by Healthcare Provider Experiences , 2011, Parkinson's disease.

[11]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[12]  T. Morioka,et al.  Assessment of Contact Location in Subthalamic Stimulation for Parkinson’s Disease by Co-Registration of Computed Tomography Images , 2008, Stereotactic and Functional Neurosurgery.

[13]  Pablo Martinez-Martin,et al.  Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients , 2007, Movement disorders : official journal of the Movement Disorder Society.

[14]  Paolo Barone,et al.  International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[15]  J. Langston,et al.  The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.

[16]  A. Benabid,et al.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.

[17]  V Sturm,et al.  Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD , 2001, Neurology.

[18]  A. Damiano,et al.  A review of health-related quality-of-life concepts and measures for Parkinson's disease , 1999, Quality of Life Research.

[19]  J. Speelman,et al.  Quality of life in patients with Parkinson's disease: development of a questionnaire. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[20]  R. Fitzpatrick,et al.  The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease , 1995, Quality of Life Research.

[21]  F. Valldeoriola,et al.  Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. , 2019, Journal of Parkinson's disease.